Suppr超能文献

体内Lp(a)修饰抑制纤维蛋白上纤溶酶形成的证据——一项针对具有Lp(a)自然变异的个体血浆的研究

Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a).

作者信息

Soulat T, Loyau S, Baudouin V, Durlach V, Gillery P, Garnotel R, Loirat C, Anglés-Cano E

机构信息

Inserm U.143, Hôpital de Bicêtre, Paris, France.

出版信息

Thromb Haemost. 1999 Jul;82(1):121-7.

Abstract

In the present study we have investigated the effect of individual variations in the concentration of Lp(a) on plasmin formation at the surface of fibrin. The plasma Lp(a) concentrations from 20 nephrotic children were high at flare-up of the disease (0.43+/-0.45 g/l) and decreased progressively with remission at both 6 weeks (0.28+/-0.24 g/l) and 6 months (0.24+/-0.288 g/l). In contrast, the concentration of plasminogen showed an inverse variation, with low values at flare-up (1.27+/-0.34 microM) and normal values at remission (1.66+/-0.17 microM at 6 weeks and 1.99+/-0.21 microM at 6 months). An increase in plasmin formation (from 0.62+/-0.49 to 0.73+/-0.61, and 0.84+/-0.75 pmol/well) and a decrease in apo(a) binding (from 5.45+/-2.42 to 4.54+/-2.12, and 3.93+/-1.51 fmol/well) on the surface of fibrin, were concomitantly observed from flare-up to remission at 6 weeks and at 6 months, respectively. Values for plasmin formation parallel the amount of plasminogen bound. The low concentration of plasminogen found at flare-up may also have contributed to the increased binding of Lp(a) as indicated by a decrease in the maximal amount of Lp(a) bound (Bmax) to fibrin as a function of plasma plasminogen concentrations. Bmax was 1.51 fmol in the absence of plasminogen and decreased to 1.1 fmol and 0.93 fmol at respectively 1 and 2 microM of plasminogen. Altogether, these data constitute the first quantitative evidence indicating that plasmin formed at the surface of fibrin may vary with modifications of the concentration of Lp(a) in vivo.

摘要

在本研究中,我们调查了纤溶酶原(Lp(a))浓度的个体差异对纤维蛋白表面纤溶酶形成的影响。20名肾病患儿在疾病发作时血浆Lp(a)浓度较高(0.43±0.45 g/l),在6周(0.28±0.24 g/l)和6个月(0.24±0.288 g/l)缓解期时逐渐降低。相反,纤溶酶原浓度呈现相反的变化,在发作时较低(1.27±0.34 microM),在缓解期时正常(6周时为1.66±0.17 microM,6个月时为1.99±0.21 microM)。从发作到6周和6个月缓解期,分别在纤维蛋白表面观察到纤溶酶形成增加(从0.62±0.49增加到0.73±0.61,以及0.84±0.75 pmol/孔)和载脂蛋白(a)结合减少(从5.45±2.42减少到4.54±2.12,以及3.93±1.51 fmol/孔)。纤溶酶形成的值与结合的纤溶酶原量平行。发作时发现的低纤溶酶原浓度也可能导致Lp(a)结合增加,这表现为与血浆纤溶酶原浓度相关的纤维蛋白结合Lp(a)的最大量(Bmax)减少。在没有纤溶酶原的情况下,Bmax为1.51 fmol,在纤溶酶原浓度分别为1 microM和2 microM时,Bmax分别降至1.1 fmol和0.93 fmol。总之,这些数据构成了首个定量证据,表明纤维蛋白表面形成的纤溶酶可能会随着体内Lp(a)浓度的改变而变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验